Effect of intracerebroventricular infusion of neurotensin in glucose-dependent insulinotropic peptide secretion in dogs

Peptides

Volumn 31, Issue 1, 2010, Pages 150-154

  Yavropoulou, Maria P ^a   Kotsa, Kalliopi ^a   Kesisoglou, Isaak ^a   Gotzamani Psarakou, Anna ^a   Yovos, John G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

GIP secretion; Icv infusion; Insulin; Neural regulation; Neurotensin

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; NEUROTENSIN;

ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOG; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION;

ANIMALS; BLOOD GLUCOSE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; INJECTIONS, INTRAVENTRICULAR; INSULIN; NEUROTENSIN; RANDOM ALLOCATION;

ANIMALIA; CANIS FAMILIARIS; FISTULA;

EID: 72749115900     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.09.029     Document Type: Article

References (26)

1. Ahren B., and Holst J.J. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 50 (2001) 1030-1038
2. Bollag R.J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141 (2000) 1228-1235
3. Bloom S. Gut hormones. 1st ed. (1978), Longman Group, Great Britain
4. Bryer-Ash M., Cheung A., and Pederson R.A. Feedback regulation of glucose-dependent insulinotropic polypeptide (GIP) secretion by insulin in conscious rats. Regul Pept 51 (1994) 101-109
5. Brown M., and Vale W. Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels. Endocrinology 98 (1976) 819-822
6. Cui H., Cai F., and Belsham D.D. Anorexigenic hormones leptin, insulin, and alpha-melanocyte-stimulating hormone directly induce neurotensin (NT) gene expression in novel NT-expressing cell models. J Neurosci 25 (2005) 9497-9506
7. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
8. Gullo L., Pezzilli R., Tomassetti P., and de Giorgio R. Plasma cholecystokinin and neurotensin after an ordinary meal in humans. A prolonged time study. Gastroenterol Clin Biol 22 (1998) 25-28
9. Hökfelt T., Everitt B.J., Theodorsson-Norheim E., and Goldstein M. Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J Comp Neurol 222 (1984) 543-559
10. Kastin A.J. Handbook of biologically active peptides. 1st ed. (2006), Elsevier Inc., USA
11. Kenney M.J., Weiss M.L., and Haywood J.R. The paraventricular nucleus: an important component of the central neurocircuitry regulating sympathetic nerve outflow. Acta Physiol Scand 177 (2003) 7-15
12. Kim E.R., Leckstrom A., and Mizuno T.M. Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice. Behav Brain Res 194 (2008) 66-71
13. Kim S.J., Nian C., and McIntosh C.H. Activation of lipoprotein lipase (LPL) by glucose-dependent insulinotropic polypeptide (GIP) in adipocytes: A role for a protein kinase B (PKB), LKB1 and AMP-activated protein kinase (AMPK) cascade. J Biol Chem 282 (2007) 8557-8567
14. Kogire M., Izukura M., Gomez G., Uchida T., Greeley Jr. G.H., and Thompson J.C. Terbutaline, a beta 2-adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs. Dig Dis Sci 35 (1990) 453-457
15. McClean P.L., Irwin N., Hunter K., Gault V.A., and Flatt P.R. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155 (2008) 690-701
16. Nagai K., and Frohman L.A. Neurotensin hyperglycemia: evidence for histamine mediation and the assessment of a possible physiologic role. Diabetes 27 (1978) 577-582
17. Salera M., Ebert R., Giacomoni P., Pironi L., Venturi S., and Corinaldesi R. Adrenergic modulation of gastric inhibitory polypeptide secretion in man. Dig Dis Sci 27 (1982) 794-800
18. Shaw C., and Buchanan K.D. Intact neurotensin (NT) in human plasma: response to oral feeding. Regul Pept 7 (1983) 145-153
19. Stanley B.G., Eppel N., and Hoebel B.G. Neurotensin-injected into the paraventricular hypothalamus suppresses feeding in rats. Ann NY Acad Sci 400 (1982) 425
20. Vahl T.P., and D'Alessio D.A. Gut peptides in the treatment of diabetes mellitus. Expert Opin Invest Drugs 13 (2004) 177-188
21. Yavropoulou M.P., Kotsa K., Kesisoglou I., Anastasiou O.E., and Yovos J.G. Intracerebroventricular infusion of neuropeptide Y increases glucose dependent-insulinotropic peptide secretion in the fasting conscious dog. Peptides 29 (2008) 2281-2285
22. Yavropoulou M.P., Kotsa K., Anastasiou O., O'Dorisio T.M., Pappas T.N., and Yovos J.G. Effect of intracerebroventricular infusion of insulin on glucose-dependent insulinotropic peptide in dogs. Neurosci Lett 460 (2009) 148-151
23. Yavropoulou M.P., Kotsa K., Anastasiou O.E., O'Dorisio T.M., Pappas T.N., and Yovos J.G. Intracerebroventricular infusion of bombesin modulates GIP secretion in conscious dogs. Neuropharmacology July (2009) [Epub ahead of print]
24. Yawata Y., Yamatani K., Tominaga M., Ebitani I., Hara M., and Sasaki H. Hyperglycemic effect of neurotensin. Tohoku J Exp Med 143 (1984) 185-196
25. Yovos J.G., O'Dorisio T.M., Gaginella T.S., Cataland S., and Carey L.C. Development and validation of an in vivo brain-gut peptide model. Regul Pept Suppl (1983) 222
26. Zhong Q., Itokawa T., Sridhar S., Ding K.H., Xie D., Kang B., et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 292 (2007) E543-E548